Patents by Inventor Thomas Preston Kennedy

Thomas Preston Kennedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7816403
    Abstract: There is provided a method for inhibiting ATF/CREB and cancer cell growth using disulfiram, administered in combination with heavy metals. It was found that disulfiram disrupts transcription factor DNA binding by forming mixed disulfides with thiols within the DNA-binding region, and that this process is facilitated by metal ions. Disulfiram administered to melanoma cells in combination with copper (II) or zinc(II) decreased expression of cyclin A, reduced proliferation in vitro, and inhibited growth of melanoma cells. The combination of oral zinc gluconate and disulfiram at currently approved doses for alcoholism stabilized tumor growth in two of three patients with Stage IV metastatic melanoma, with 12 and 17 month survivals, respectively, to date, and produced a >50% reduction in hepatic metastases in one individual.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: October 19, 2010
    Assignee: University of Utah Research Foundation
    Inventor: Thomas Preston Kennedy
  • Patent number: 7468358
    Abstract: A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin-and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: December 23, 2008
    Assignee: Paringenix, Inc.
    Inventors: Thomas Preston Kennedy, Jeanine M. Walenga
  • Patent number: 6987127
    Abstract: Malignant melanoma cells spontaneously generate reactive oxygen species (ROS) that promote constitutive activation of the transcription factor nuclear factor-kB (NF-kB). Although antioxidants and inhibitors of NAD(P)H oxidases significantly reduce constitutive NF-kB activation and suppress cell proliferation, the nature of the enzyme responsible for ROS production in melanoma cells has not been determined. To address this issue, we now have characterized the source of ROS production in melanoma cells. ROS are generated by isolated, cytosol-free melanoma plasma membranes, with inhibition by NAD(P)H oxidase inhibitors. The p22phox, gp91phox and p67phox components of the human phagocyte NAD(P)H oxidase, and the 91phox homolog NOX4 were demon-strated in melanomas by RT-PCR and sequencing, and protein product for both p22phox and gp91phox were detected in cell membranes by immunoassay. Normal human epidermal melanocytes expressed only p22phox and NOX4.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: January 17, 2006
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Publication number: 20040171678
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: February 25, 2004
    Publication date: September 2, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Patent number: 6706759
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: March 16, 2004
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Publication number: 20040047852
    Abstract: Methods for treating cancer are provided including administering a patient needing treatment a therapeutically effective amount of one or more antioxidants selected from the group of catalase, N-acetylcysteine, glutathione peroxidase, salen-transition metal complexes, dicumarol, and derivatives thereof.
    Type: Application
    Filed: September 3, 2003
    Publication date: March 11, 2004
    Inventor: Thomas Preston Kennedy
  • Publication number: 20040019102
    Abstract: There is provided a method for inhibiting ATF/CREB and cancer cell growth using disulfiram, administered in combination with heavy metals. It was found that disulfiram disrupts transcription factor DNA binding by forming mixed disulfides with thiols within the DNA-binding region, and that this process is facilitated by metal ions. Disulfiram administered to melanoma cells in combination with copper (II) or zinc(II) decreased expression of cyclin A, reduced proliferation in vitro, and inhibited growth of melanoma cells. The combination of oral zinc gluconate and disulfiram at currently approved doses for alcoholism stabilized tumor growth in two of three patients with Stage IV metastatic melanoma, with 12 and 17 month survivals, respectively, to date, and produced a >50% reduction in hepatic metastases in one individual.
    Type: Application
    Filed: May 14, 2003
    Publication date: January 29, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Publication number: 20030229064
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: March 3, 2003
    Publication date: December 11, 2003
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Patent number: 6589987
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide strongly inhibits the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: July 8, 2003
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Patent number: 6548540
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 15, 2003
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Publication number: 20010016600
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: December 12, 2000
    Publication date: August 23, 2001
    Inventor: Thomas Preston Kennedy